Tirzepatide in metabolic alcohol-related liver disease
About this title
Read the official source — NCT07046819Understand this study
Who could participate?
Listed age limits: 21 years to 100 years.
What will I do during this study?
You receive a weekly injection under the skin of tirzepatide or saline for 12 weeks, depending on your assigned group. The study measures changes in body weight and liver fat from baseline to week 12.
- Listed locations
- BethesdaSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 21 Years to 100 Years
- Official registry ID
- NCT07046819
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo-Controlled, Flexible Dose Phase 2 Study of Efficacy and Safety of Tirzepatide in Individuals With Alcohol Use Disorder and Metabolic Alcohol-associated Liver Disease
Recruitment & locations
Bethesda
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), a research institute.
Does this study involve medication?
Yes. The study involves medication, including Tirzepatide.
Who can participate?
Listed age limits: 21 years to 100 years.
Is this study still recruiting?
The registry lists this study as recruiting.
